Artwork

Content provided by Qualio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Qualio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Getting Treatments to Patients Faster by Focusing on Your Strengths with Keith Woods

20:21
 
Share
 

Manage episode 359277586 series 2833485
Content provided by Qualio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Qualio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

There’s no question that 2022 was a tumultuous year for biotech companies. As 2023 is underway, we're talking to Keith Woods, former COO and current strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on), a biotech company whose strong earnings come amid a downturn for the wider market and especially the biotech industry in 2022.
While other companies continue to face challenges in this climate, this biotech is hitting its stride – argenx has managed rapid growth, and a successful drug launch.
One major factor driving argenx’s success: argenx’s seasoned COO Keith Woods and his management philosophy of sustainable growth.
https://www.argenx.com/
https://www.linkedin.com/in/keith-woods-5b8b67117/
More about Keith
Keith is was COO since 2018 and is currently a strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on). He comes with 25+ years of leadership experience in the biopharmaceutical industry, with the likes of Alexion, Roche, and Amgen. He has sage advice to offer about navigating market downturns, while still managing to grow and scale sustainably.
**UPDATE** After recording this interview Keith transitioned from COO to Advisor on the argenx Board of Directors. https://www.globenewswire.com/news-release/2023/03/02/2618906/0/en/argenx-Announces-Planned-Transition-of-Chief-Operating-Officer.html
About argenx
The team at Argenx has created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies. We’ll get more into their discoveries, culture, and how our listeners can bring about innovation by focusing more and more on patients.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

  continue reading

116 episodes

Artwork
iconShare
 
Manage episode 359277586 series 2833485
Content provided by Qualio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Qualio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

There’s no question that 2022 was a tumultuous year for biotech companies. As 2023 is underway, we're talking to Keith Woods, former COO and current strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on), a biotech company whose strong earnings come amid a downturn for the wider market and especially the biotech industry in 2022.
While other companies continue to face challenges in this climate, this biotech is hitting its stride – argenx has managed rapid growth, and a successful drug launch.
One major factor driving argenx’s success: argenx’s seasoned COO Keith Woods and his management philosophy of sustainable growth.
https://www.argenx.com/
https://www.linkedin.com/in/keith-woods-5b8b67117/
More about Keith
Keith is was COO since 2018 and is currently a strategic advisor on the Commercial Committee of the argenx Board of Directors (from 3/13 on). He comes with 25+ years of leadership experience in the biopharmaceutical industry, with the likes of Alexion, Roche, and Amgen. He has sage advice to offer about navigating market downturns, while still managing to grow and scale sustainably.
**UPDATE** After recording this interview Keith transitioned from COO to Advisor on the argenx Board of Directors. https://www.globenewswire.com/news-release/2023/03/02/2618906/0/en/argenx-Announces-Planned-Transition-of-Chief-Operating-Officer.html
About argenx
The team at Argenx has created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies. We’ll get more into their discoveries, culture, and how our listeners can bring about innovation by focusing more and more on patients.

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

  continue reading

116 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play